BAZ2-ICR
BAZ2-ICR 性质
| 沸点 | 632.8±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.26±0.1 g/cm3(Predicted) |
| 溶解度 | DMSO:18.58(最大浓度 mg/mL);51.99(最大浓度 mM) DMF:20.0(最大浓度 mg/mL);55.96(最大浓度 mM) DMF:PBS ( pH 7.2) (1:1):0.5(最大浓度 mg/mL);1.4(最大浓度 mM) 乙醇:13.37(最大浓度 mg/mL);37.41(最大浓度 mM) |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 4.29±0.61(Predicted) |
BAZ2-ICR 用途与合成方法
IC50: 130 nM (BAZ2A) and 180 nM (BAZ2B); Kd: 109 nM (BAZ2A) and 170 nM (BAZ2A)
To investigate whether BAZ2-ICR (Compound 13) can displace BAZ2 bromodomains from chromatin in living cells, a fluorescence recovery after photobleaching (FRAP) assay utilizing GFP-tagged BAZ2A full length protein transfected into human osteosarcoma cells (U2OS) are tested. 1 μM BAZ2-ICR reduces the recovery time of the wild-type (wt) construct to a level similar to the dominant negative mutant, confirming that BAZ2-ICR inhibits BAZ2A in cells.
BAZ2-ICR (Compound 13) shows very high solubility (25 mM in D2O), a measured log D of 1.05, high stability in mouse microsomes, and permeation in the CaCo-2 model and thus a suitable profile for oral and intravenous gavage. BAZ2-ICR (5 mg/kg) shows 70% bioavailability and moderate clearance (∼50% of mouse liver blood flow) and volume of distribution.
BAZ2-ICR 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-19336 | 1 mg | 1590 | ||
| 2024-01-25 | HY-19336 | BAZ2-ICR | 1665195-94-7 | 5mg | 3500 |
